Overview
Psilocybin, the psychoactive compound found in certain mushrooms, continues to attract scientific interest as a possible treatment for depression that has not improved with standard care. The EPISODE randomized clinical trial examined whether a single oral dose of psilocybin, given with psychotherapy, could reduce symptoms in adults with treatment-resistant major depression. The study found that psilocybin 25 mg was associated with a clinically meaningful reduction in depressive symptoms, but it did not meet the study’s primary statistical endpoint. Safety findings also showed that adverse events were more common around dosing, and suicidal ideation was reported more often on dosing days in the psilocybin group.
Why this study matters
Major depressive disorder is one of the leading causes of disability worldwide. For many people, standard treatments such as antidepressants, psychotherapy, and lifestyle support are effective. However, a substantial subgroup does not respond adequately to multiple treatment attempts. This condition is known as treatment-resistant depression, or TRD.
TRD can be especially challenging because persistent depressive symptoms are linked to functional impairment, social withdrawal, reduced quality of life, and increased risk of suicide. Researchers have therefore been studying novel approaches, including psychedelic-assisted therapy. Psilocybin has been reported in earlier studies to produce rapid antidepressant effects, but prior trials have had limitations such as small sample sizes, limited blinding, and short follow-up. The EPISODE trial was designed to address some of those gaps.
Study design
This was a phase 2b, two-center, triple-blinded, active placebo-controlled randomized clinical trial conducted in Germany. Triple blinding meant that investigators, participants, and raters were blinded to treatment assignment. The study enrolled adults aged 25 to 65 years with treatment-resistant depression who had withdrawn from antidepressant medication before participation.
Participants were randomized in a 2:2:1:1 ratio to one of four dosing sequences, with two sessions six weeks apart. The main groups reported in the efficacy analysis were:
1. Psilocybin 25 mg, followed later by psilocybin 25 mg or a comparator sequence depending on randomization group
2. Psilocybin 5 mg, followed by psilocybin 25 mg
3. Nicotinamide 100 mg as an active placebo, followed by psilocybin 25 mg
For the primary efficacy analysis before the second dose, the comparison focused on the first session outcome at week 6. Oral psilocybin was always administered with psychotherapeutic support, reflecting current interest in psychedelic treatment as a combined biological and psychological intervention rather than as a standalone drug.
How the treatment was given
The intervention used synthetic oral psilocybin in capsule form. The 25 mg dose was intended as the active therapeutic dose, while 5 mg served as a low-dose comparator and nicotinamide served as an active placebo to help preserve blinding. All dosing sessions took place in a psychotherapeutic setting, which likely included preparation before dosing, support during the acute experience, and integration afterward.
This is important because the subjective effects of psilocybin can be intense and may include changes in mood, perception, and thought patterns. Psychotherapy is believed to help patients process these experiences safely and may contribute to therapeutic benefit.
Main outcomes
The primary endpoint was treatment response at week 6, defined as at least a 50% reduction in score on the 17-item Hamilton Rating Scale for Depression, or HAMD17. This scale is widely used in depression research and measures symptom severity. Key secondary endpoints included response on the Beck Depression Inventory II, or BDI-II, and mean change from baseline on both the HAMD17 and BDI-II at week 6.
The primary efficacy population included 142 participants. The average age was 42.6 years, and 59.0% were men. In the primary analysis, response rates were:
– Psilocybin 25 mg: 17.0%
– Psilocybin 5 mg: 12.5%
– Nicotinamide: 10.6%
The first planned hierarchical comparison, psilocybin 25 mg versus nicotinamide, was not statistically significant. The adjusted odds ratio was 1.73 with a 95% confidence interval of 0.53 to 6.23, and the reported P value was .19. Because this comparison was nonsignificant, the study did not proceed with further formal confirmatory testing.
Even so, analyses of the secondary outcomes suggested a clinically meaningful reduction in depressive symptoms with psilocybin 25 mg. In practical terms, this means that the treatment may have helped some participants feel better, but the study was not able to prove this effect with the statistical certainty required for its primary endpoint.
Interpreting the results
The trial’s results are best described as promising but inconclusive. The lack of a statistically significant primary result does not mean psilocybin has no effect. Rather, it means that this particular trial did not provide sufficient confirmatory evidence under its predefined testing plan.
Several factors may have influenced the outcome. Depression is a heterogeneous illness, and treatment-resistant cases vary widely in severity, duration, comorbidity, and prior treatment history. Blinding in psychedelic studies is also difficult because the active drug usually produces noticeable effects, which can influence expectations and responses. In addition, the relatively low response rates across all groups suggest that placebo and psychotherapy effects may have contributed meaningfully.
Still, the pattern of secondary findings supports continued research, especially in carefully designed trials with longer follow-up, improved outcome measures, and better ways to maintain blinding.
Safety findings
Safety is a central issue in psychedelic research. In this study, psilocybin 25 mg was associated with adverse events, mostly occurring acutely around the time of dosing. This pattern is consistent with the known time course of psilocybin’s effects, which typically begin within a few hours and then wear off over the course of the day.
A notable safety signal was a higher report of suicidal ideation on dosing days in the psilocybin group, at 4%, compared with 1% to 2% in comparator conditions. This does not automatically prove a causal relationship, but it underscores the need for careful monitoring, especially in people with severe depression.
Two serious adverse reactions were reported after psilocybin 25 mg, including one case of hallucinogen persisting perception disorder, a condition in which visual disturbances can persist after the drug has worn off. Although rare, this adverse effect is clinically important because it can affect quality of life and may be distressing.
Overall, most participants tolerated the treatment, but the safety profile shows that psilocybin is not a benign or risk-free intervention. Its use requires structured supervision, screening for psychiatric and medical contraindications, and follow-up after dosing.
What this means for patients and clinicians
For patients with treatment-resistant depression, the EPISODE trial adds to a growing body of evidence suggesting that psilocybin-assisted therapy may help reduce depressive symptoms in some individuals. However, it is not yet a standard treatment. The findings do not establish psilocybin as clearly effective, and the safety concerns mean that unsupervised or recreational use is not appropriate.
For clinicians, this study reinforces several practical points:
– Psilocybin should be considered investigational for depression at this stage.
– Psychological support is likely to be an essential part of any therapeutic model.
– Safety monitoring must include attention to acute anxiety, suicidal ideation, blood pressure changes, perceptual disturbances, and persistent psychiatric symptoms.
– Patients with TRD may benefit from referral to specialized centers or clinical trials when available.
Relation to other depression treatments
Current evidence-based treatments for major depression include antidepressant medications, structured psychotherapy, electroconvulsive therapy, transcranial magnetic stimulation, ketamine-based approaches in selected cases, and, for some patients, augmentation strategies. Psilocybin differs from these options because it is usually delivered in one or two supervised sessions rather than as a daily medication.
That dosing model is appealing, but it also raises important questions. How durable are the benefits? Which patients are most likely to respond? What psychotherapy components are necessary? How can safety be ensured in real-world settings? The EPISODE trial contributes useful information, but it does not yet answer these broader questions.
Study limitations
Several limitations should be kept in mind. First, the sample size was modest for a psychiatric trial, which limits statistical power. Second, the study used an active placebo, but blinding may still have been imperfect because psilocybin produces noticeable subjective effects. Third, the report reflects outcomes at week 6 before the second dose, so longer-term benefits and risks are not fully captured here. Fourth, the trial population was recruited mostly from two outpatient settings in Germany, which may limit generalizability to other health systems and cultural contexts.
Despite these limitations, the study was methodologically strong in several respects, including randomization, triple blinding, and use of a comparative placebo design. These features strengthen confidence in the validity of the reported findings.
Bottom line
The EPISODE randomized clinical trial found that psilocybin 25 mg with adjunct psychotherapy was associated with a meaningful reduction in depressive symptoms in treatment-resistant major depression, but it did not achieve statistical significance on its primary endpoint. Most participants tolerated the treatment, yet adverse events, suicidal ideation on dosing days, and rare serious reactions highlight the need for caution.
In short, psilocybin remains a promising but still experimental option for depression. The study adds important evidence to the field, but larger and longer trials are needed before it can be considered a routine treatment.
Trial information
ClinicalTrials.gov Identifier: NCT04670081
Published in JAMA Psychiatry, May 2026.